Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 88-CIRCULATE PAC
2023-505046-26-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- May 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trifluridine + tipiracil, irinotecan, fluorouracil, folinic acid and bevacizumab in colorectal cancer (CRC), colon adenocarcinoma and rectal adenocarcinoma (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Time to recurrence. Planned start May 2026; status: authorised.
02
Drugs
trifluridine + tipiracilirinotecanfluorouracilfolinic acidbevacizumab
03
Conditions
colorectal cancer (CRC)colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2023-505046-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505046-26-00.